Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
life sciences
novartis
3
×
abbvie
astrazeneca
boulder/denver blog main
boulder/denver top stories
cancer
covid-19
deals
detroit blog main
detroit top stories
europe blog main
europe top stories
gilead sciences
indiana blog main
indiana top stories
martin shkreli
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
takeda pharmaceutical
texas blog main
texas top stories
unity biotechnology
wisconsin blog main
wisconsin top stories
akouos
What
sciences
3
×
acquisitions
bio
ceo
daniel
drug
gilead
o’day
roundup
announced
biggest
biotech
build
buy
collabs
company’s
covid
deal
debut
driving
dyne’s
gilead’s
good
healthcare
help
history
improved
industry
innovation
innovations
introduce
investment
ipo
life
long
medical
medicines
microbiome
month
moves
Language
unset
Current search:
novartis
×
sciences
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good